Drug
LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION is a pharmaceutical drug with 2 clinical trials. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
1
50%
Ph phase_3
1
50%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 3Large-scale testing
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
2
all time
Status Distribution
Completed(2)
Detailed Status
Completed2
Development Timeline
Analytics
Development Status
Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 31 (50.0%)
N/A1 (50.0%)
Trials by Status
completed2100%
Recent Activity
0 active trials
Showing 2 of 2
completedphase_3
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
NCT00230763
completednot_applicable
Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
NCT00706927
Clinical Trials (2)
Showing 2 of 2 trials
NCT00230763Phase 3
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
NCT00706927Not Applicable
Effect of Xalacom® (Latanoprost/Timolol) and Combigan® (Brimonidine/Timolol) Fixed Combination on Intraocular Pressure and Ocular Blood Flow in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2